



March 20, 2008

Dear Passport Health Plan Provider,

This letter is to inform you that the Bayer Group has withdrawn the **liquid formulation** of the medication Leukine™ from U.S. markets. This withdrawal is due to an upward trend in adverse events and is not associated with the **lyophilized formulation** of Leukine™.

Passport Health Plan has informed all members who recently received Leukine™ to contact their health care provider to determine future action based on this withdrawal.

It may be necessary for you to change Passport Health Plan members to another agent. All formulary agents in this class will require prior authorization. Our current formulary alternatives are:

- Neupogen® (filgrastim)
- Neulasta® (peg-filgrastim)

We hope this information is useful. If you have any questions regarding this change, please call (800) 578-0898 to speak with one of our clinical pharmacists. As always, your continued cooperation is greatly appreciated.

Sincerely,

A handwritten signature in black ink, appearing to read "Thomas Kaye".

Thomas Kaye, RPh., MBA
Senior Pharmacy Director

